Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Friday, May 30, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward hematologists/oncologists, medical oncologists, and other HCPs involved in the treatment and management of MM.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze efficacy and safety data from pivotal trials evaluating new and emerging therapies for relapsed/refractory multiple myeloma (R/R MM)
- Balance disease- and patient-specific factors to formulate individualized treatment plans for patients with early relapsed MM
- Incorporate evidence-based strategies to select and sequence T-cell therapies for heavily pretreated patients with R/R MM
- Implement proactive measures to mitigate treatment-related toxicities in patients with R/R MM
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from AbbVie, Inc.
Physicians’ Education Resource® is proud to partner with the International Academy for Clinical Hematology
